FGF21 and Cardiac Physiopathology

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Fibroblast growth factor-21 (FGF21) was not traditionally considered a cardiac factor.
• Recent research reveals FGF21 acts as a cardiomyokine, produced by cardiac cells and acting on the heart itself.

Purpose of the Study:

• To explore the novel role of FGF21 as a cardiomyokine.
• To investigate the protective effects of FGF21 in cardiac conditions.
• To understand the regulation and clinical relevance of FGF21 in heart disease.

Main Methods:

• Investigated FGF21 production and action in cardiac cells.
• Examined FGF21's role in response to cardiac insults (e.g., hypertrophy, myocardial infarction).
• Analyzed intracellular mechanisms (PPARα, Sirt1) regulating FGF21 gene expression.
• Assessed circulating FGF21 levels in human cardiovascular disease.

Main Results:

• The heart produces FGF21, which acts autocrinely on cardiac cells via β-Klotho co-receptor.
• FGF21 demonstrates protective effects against cardiac hypertrophy, inflammation, and oxidative stress.
• FGF21 expression increases in the heart following injury and in failing human hearts.
• Elevated FGF21 levels correlate with coronary heart disease, atherosclerosis, and cardiovascular risk in type 2 diabetes patients.

Conclusions:

• FGF21 functions as a cardiomyokine with significant protective roles in the heart.
• Cardiac FGF21 signaling, regulated by intracellular pathways, is crucial for cardiac health.
• Circulating FGF21 levels serve as a biomarker for cardiovascular risk.
• FGF21 presents a promising therapeutic target for various cardiac diseases.